Category Archives: Ulcerative Colitis

ASACOL an effective treatment for Ulcerative colitis, Proctosis and Proctosigmoiditis http://goo.gl/McmYWg. By: … Continue reading →

Use Asacol to Get Rid Of Ulcerative Colitis http://goo.gl/McmYWg. By: … Continue reading →

Treat ulcerative colitis with Asacol http://goo.gl/McmYWg. By: … Continue reading →

- 18 abstract presentations including vedolizumab safety and efficacy data ZURICH, Feb. 20, 2015 /PRNewswire/ --Takeda Pharmaceuticals International GmbH ("Takeda") today announced the presentation of data further demonstrating the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). Findings from the Phase 3 pivotal GEMINI 1 (ulcerative colitis) and GEMINI 2 (Crohn's disease) studies, as well as interim data from the ongoing, open-label extension study GEMINI LTS (long-term safety) were presented as oral digital presentations and poster presentations during the 10th Congress of European Crohn's and Colitis Organisation (ECCO) in Barcelona, Spain. A total of 18 Takeda-sponsored abstracts were accepted for presentation at the meeting. "As ulcerative colitis and Crohn's disease are so complex to treat, ongoing scientific study and exchange are important to further understand the clinical benefits of vedolizumab," said Prof. Dr. Severine Vermeire, University Hospitals Leuven, Belgium. "These findings signify its promise as an important treatment option for patients." The GEMINI 1 and 2 studies are two randomized double-blind, placebo-controlled induction and maintenance studies examining the efficacy and safety of vedolizumab for induction and maintenance in adult patients with moderately to severely active UC … Continue reading →

Buy Asacol online, the best treatment for ulcerative colitis http://goo.gl/McmYWg. By: … Continue reading →

IIFYM - Full Day of Eating with Ulcerative Colitis Twitter: @rkannese. By: Rob Annese … Continue reading →

Buy Asacol Online prevent ulcerative colitis http://goo.gl/McmYWg. By: … Continue reading →

BARCELONA and MADRID, Spain (ots) - - Hungarian National Registry reports interim results following Inflectra therapy in 90 patients with Crohn's disease and ulcerative colitis - These data add to the growing body of evidence supporting the efficacy and safety of Inflectra treatment in inflammatory bowel disease Data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (mAb), at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference (https://www.ecco-ibd.eu/ecco15). Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade(R) (infliximab), for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease (IBD). Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, (57 with CD and 33 with UC) treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment.[1]* C-reactive protein (CRP), a marker of inflammation, was also decreased during induction therapy for UC.[1] Four of the 90 patients showed an allergic reaction … Continue reading →

BARCELONA and MADRID, Spain (ots) - Data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first approved biosimilar monoclonal antibody (mAb), at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference (https://www.ecco-ibd.eu/ecco15). Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade(R) (infliximab), for inducing and maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease (IBD). Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, (57 with CD and 33 with UC) treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment.[1]* C-reactive protein (CRP), a marker of inflammation, was also decreased during induction therapy for UC.[1] Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti- TNF medication.[1] The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort ( https://www.ecco-ibd.eu/index.php/publications/congress-abstract-s/item/p314-biosimilar-infliximab-in-inflammatory-bowel-diseases-first-interim-results-from-a-prospective-nationwide-observational-cohort.html?highlight=YToxOntpOjA7czo0OiJwMzE0Ijt9 ). Professor Peter Lakatos, one of … Continue reading →

Asacol helps to prevent ulcerative colitis http://goo.gl/McmYWg. By: … Continue reading →